goat anti rat ccl2 polyclonal antibody  (Bioss)

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: ( A ) Number of genes by mRNA expression level in the NiO-high dose group at one month. ( B ) Description of the genes that are related to ‘inflammatory response’ among the 16 genes upregulated ≧ 8-fold.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Gene expression of five chemokines in lung exposed to nanomaterials with different pulmonary toxicities. ( A ) CXCL5 mRNA expression (Low dose group); ( B ) CXCL5 mRNA expression (High dose group); ( C ) CCL2 mRNA expression (Low dose group); ( D ) CCL2 mRNA expression (High dose group); ( E ) CCL7 mRNA expression (Low dose group); ( F ) CCL7 mRNA expression (High dose group); ( G ) CXCL10 mRNA expression (Low dose group); ( H ) CXCL10 mRNA expression (High dose group); ( I ) CXCL11 mRNA expression (Low dose group); ( J ) CXCL11 mRNA expression (High dose group). Data, normalized to β-actin endogenous control, are presented as fold change relative to the negative controls (distilled water). Values changes are mean ± standard deviation (SD) ( p < 0.05, n = 5). Increased expression of CXCL5 gene in the NiO and CeO 2 groups was persistently higher, and that in the TiO 2 and ZnO groups transiently higher compared with the negative control groups, respectively. CCL2 and CCL7 also showed a similar tendency to CXCL5 (* p < 0.05, ** p < 0.01). The low dose groups: 0.2 mg; the high dose groups: 1.0 mg. Value of approximate 1 × 10 0 means the negative control.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing, Standard Deviation, Negative Control

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: p values of gene expression of 5 chemokines in lung exposed to nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Receiver operating characteristic (ROC) analysis between gene expression and pulmonary toxicity of nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Sensitivity and specificity of gene expression of five chemokines in the pulmonary toxicity of nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Representative images of CXCL5, CCL2, and CCL7 immunostaining in lung tissue exposed to NiO. ( A – D ): the negative control lungs; ( A ) H&E staining; ( B ) CXCL5 immunostaining; ( C ) CCL2 immunostaining; (D)CCL7 immunostaining. ( E – H ): the NiO-high dose exposed lungs; ( E ) H&E staining; ( F ) CXCL5 immunostaining; ( G ) CCL2 immunostaining; ( H ) CCL7 immunostaining. All of the examples illustrate findings at 1 month after intratracheal instillation: Positive cells of CXCL5, CCL2, and CCL7 immunostaining on NiO-exposed lungs were mainly macrophages. (internal scale bar = 100 μm for all).

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Immunostaining, Negative Control, Staining

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Relationship between inflammatory cell infiltration and gene expression of each 5 chemokines in exposed lung. ( A ) CXCL5 mRNA expression, ( C ) CCL2 mRNA expression, ( E ) CCL7 mRNA expression, ( G ) CXCL10 mRNA expression, ( I ) CXCL11 mRNA expression at 1 week after the instillation versus score of inflammatory cell infiltration and ( B ) CXCL5 mRNA expression, ( D ) CCL2 mRNA expression, ( F ) CCL7 mRNA expression, ( H ) CXCL10 mRNA expression, ( J ) CXCL11 mRNA expression at 1 month after the instillation versus score of inflammatory cell infiltration. There was relatively good correlation between inflammatory cell infiltration in lung tissues and CXCL5 , CCL2 , and CCL7 at one week and one month after intratracheal instillation.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: ( A ) Number of genes by mRNA expression level in the NiO-high dose group at one month. ( B ) Description of the genes that are related to ‘inflammatory response’ among the 16 genes upregulated ≧ 8-fold.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Expressing, Control

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Gene expression of five chemokines in lung exposed to nanomaterials with different pulmonary toxicities. ( A ) CXCL5 mRNA expression (Low dose group); ( B ) CXCL5 mRNA expression (High dose group); ( C ) CCL2 mRNA expression (Low dose group); ( D ) CCL2 mRNA expression (High dose group); ( E ) CCL7 mRNA expression (Low dose group); ( F ) CCL7 mRNA expression (High dose group); ( G ) CXCL10 mRNA expression (Low dose group); ( H ) CXCL10 mRNA expression (High dose group); ( I ) CXCL11 mRNA expression (Low dose group); ( J ) CXCL11 mRNA expression (High dose group). Data, normalized to β-actin endogenous control, are presented as fold change relative to the negative controls (distilled water). Values changes are mean ± standard deviation (SD) ( p < 0.05, n = 5). Increased expression of CXCL5 gene in the NiO and CeO 2 groups was persistently higher, and that in the TiO 2 and ZnO groups transiently higher compared with the negative control groups, respectively. CCL2 and CCL7 also showed a similar tendency to CXCL5 (* p < 0.05, ** p < 0.01). The low dose groups: 0.2 mg; the high dose groups: 1.0 mg. Value of approximate 1 × 10 0 means the negative control.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Gene Expression, Expressing, Control, Standard Deviation, Negative Control

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: p values of gene expression of 5 chemokines in lung exposed to nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Gene Expression

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Receiver operating characteristic (ROC) analysis between gene expression and pulmonary toxicity of nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Gene Expression

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Sensitivity and specificity of gene expression of five chemokines in the pulmonary toxicity of nanomaterials.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Gene Expression

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Representative images of CXCL5, CCL2, and CCL7 immunostaining in lung tissue exposed to NiO. ( A – D ): the negative control lungs; ( A ) H&E staining; ( B ) CXCL5 immunostaining; ( C ) CCL2 immunostaining; (D)CCL7 immunostaining. ( E – H ): the NiO-high dose exposed lungs; ( E ) H&E staining; ( F ) CXCL5 immunostaining; ( G ) CCL2 immunostaining; ( H ) CCL7 immunostaining. All of the examples illustrate findings at 1 month after intratracheal instillation: Positive cells of CXCL5, CCL2, and CCL7 immunostaining on NiO-exposed lungs were mainly macrophages. (internal scale bar = 100 μm for all).

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Immunostaining, Negative Control, Staining

Journal: Nanomaterials

Article Title: Predictive Biomarkers for the Ranking of Pulmonary Toxicity of Nanomaterials

doi: 10.3390/nano10102032

Figure Lengend Snippet: Relationship between inflammatory cell infiltration and gene expression of each 5 chemokines in exposed lung. ( A ) CXCL5 mRNA expression, ( C ) CCL2 mRNA expression, ( E ) CCL7 mRNA expression, ( G ) CXCL10 mRNA expression, ( I ) CXCL11 mRNA expression at 1 week after the instillation versus score of inflammatory cell infiltration and ( B ) CXCL5 mRNA expression, ( D ) CCL2 mRNA expression, ( F ) CCL7 mRNA expression, ( H ) CXCL10 mRNA expression, ( J ) CXCL11 mRNA expression at 1 month after the instillation versus score of inflammatory cell infiltration. There was relatively good correlation between inflammatory cell infiltration in lung tissues and CXCL5 , CCL2 , and CCL7 at one week and one month after intratracheal instillation.

Article Snippet: The upregulation of CXCL5 , CCL2 , and CCL7 was evaluated by immunostaining with rabbit anti-mouse CXCL5 polyclonal antibody (1:200 dilution, bs-2549R; Bioss Inc., Woburn, MA, USA), goat anti-rat CCL2 polyclonal antibody (1:200 dilution, sc-1785; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), and goat anti-mouse CCL7 polyclonal antibody (1:50 dilution, sc-21202; Santa Cruz Biotechnologies, Inc., Dallas, CA, USA), respectively, while using the lung tissue samples from the NiO-high dose group of one month after intratracheal instillation.

Techniques: Gene Expression, Expressing